New test could transform diagnosis and treatment of STIs
A new rapid test for sexually transmitted infections could soon transform on-the-spot diagnosis and treatment.
Birmingham-based Linear Diagnostics has secured £1 million in funding to develop the technology, which could deliver results in less than 20 minutes.
The funding comes from the NIHR Invention for Innovation programme and will support a three-year project to finalise the test and prepare it for clinical trials.
Dr Jean-Louis Duprey, head of research and development at Linear Diagnostics, said: "We are developing a near patient device that will overcome this conundrum."
The company is working with the NIHR HealthTech Research Centre and the North East Innovation Lab to deliver the project.
Dr Jana Suklan, senior methodologist at the HRC, said: "The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology.
"Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology."
The test uses Linear's Exponential Amplification (EXPAR) technology, which detects bacterial DNA within minutes.
The company has focused on STIs such as Neisseria gonorrhoeae and Chlamydia trachomatis, where rapid diagnosis is essential to prevent further transmission and begin treatment immediately.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Here Are The 9 States Being Hit With The Latest Egg Recall
Egg price decreases have been slow to arrive at grocery stores nationwide. Over the past two months, prices have finally begun to cool and a multi-state salmonella outbreak is just the punctuation mark to months of relentless eggflation that weary consumers don't need. But, it's what they've got! According to an official FDA announcement on June 6, nearly 2 million dozen egg cartons are being pulled from shelves due to a mass salmonella contamination risk. As if consumers weren't feeling wary enough, the specific recalled product is 1.7 million dozen brown, cage-free, certified organic eggs -- health-centric buzzwords that make customers feel like they're purchasing a product they can trust. This latest salmonella outbreak risk exponentially compounds the growing issue of consumer trust in food safety. For the first time since October 2024, month-to-month dozen egg prices finally decreased from $6.23 in March to $5.12 in April -- a national average price which still remains at a historic high. Eggflation was due largely in part to a shortage caused by an avian flu outbreak, which makes this latest recall of millions of eggs feel somehow even worse. The outbreak traces back to August Egg Company, a California-based manufacturer. As of June 5, the CDC has reported 79 cases of illness spanning seven states. The affected eggs were sold at Walmart stores in nine states: Arizona, California, Illinois, Indiana, Nebraska, Nevada, New Mexico, Washington, and Wyoming, as well as several other grocery chains concentrated in California and Nevada. Read more: 12 Gluten-Free Pasta Brands, Ranked Worst To Best Twenty-one of the 79 ill consumers have been hospitalized, and the CDC estimates that the actual number of sickened people is much higher. Consumers reported becoming ill between February 24, 2025 and May 17, 2025. Luckily, as an exercise in reducing food waste on such a mass scale, the August Egg Company "immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens," per a statement from the company, as reported by the FDA. To stay safe, people who have recently purchased eggs from Walmart should check their cartons for sell-by dates between March 4, 2025 and June 19, 2025. Foodies who have purchased eggs from grocery chains Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less, or Ralphs should look for sell-by dates from March 4, 2025 to June 4, 2025. The packages of affected eggs will be printed with the plant code number P-6562 or CA5330 with the Julian Dates between 32 and 126. A full list of affected plant numbers and UPCs is included in the FDA report. Shoppers who spy any of the above details on their egg cartons are being instructed to return the product to its place of purchase for a full refund. To be safe, sanitize all surfaces with which the affected product might have come into contact. Read the original article on Tasting Table.
Yahoo
an hour ago
- Yahoo
Gilbane, F.A. Wilhelm top out $4.3B Indianapolis hospital
This story was originally published on Construction Dive. To receive daily news and insights, subscribe to our free daily Construction Dive newsletter. A joint venture of Providence, Rhode Island-based Gilbane Building Co. and Indianapolis-based F.A. Wilhelm topped out Indiana University Health's new downtown Indianapolis hospital, according to a May 27 Gilbane news release. The $4.3 billion, 2.1 million-square-foot hospital, announced in August 2020, will contain 864 inpatient rooms, 50 operating rooms and two helipads, according to Gilbane's project page. It will combine the health system's Methodist and University Hospitals, and is on track to finish in 2027, according to a June 2024 construction update. The medical project, initially budgeted at $1.6 billion, swelled to $4.3 billion in 2023. Growing construction costs of more than 20% of the initial budget and a height increase in the hospital's three bed towers to 16 stories initially increased it to $2.31 billion, according to a 2023 news release from the hospital network. Along with those construction costs, support buildings and other infrastructure — which include medical offices, parking garages and logistics space — tacked on an additional $1.98 billion to the project's price tag, per the news release. Combined, the inflated costs and additional work more than doubled the original budget. The hospital will also feature three clinical institutes for cancer, cardiovascular and neuroscience care, according to the hospital's project page. The complex will include bridges to the Capitol View medical office building, the Indiana University School of Medicine and the South Support Building, per Gilbane. At a lower level, below-grade tunnels will traverse from the hospital to the School of Medicine, South Support Building and central utility plant. 'Reaching the topping-out milestone is a proud moment for our entire team,' said Aaron Perry, Gilbane's project director, in the release. 'It reflects years of hard work, coordination, and a shared dedication to safety and quality.' Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. Related L'Oréal acquires Galderma stake and targets the injectables market The Body Shop goes into administration, with hundreds of UK jobs at risk This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
